ASCO Lung Cancer 2022 – John Varlotto
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationJohn Varlotto summarizes which insights have been obtained based on recent studies regarding immunotherapy plus chemoradiation in patients with unresectable or locally advanced stage III non-small cell lung cancer, explains the different effect observed with pemrolizumab and nivolumab and how these results compare to existing data. He discusses if we can extend pathologic complete response rates as well as neoadjuvant chemoimmunotherapy to the unresectable setting and if individualization of therapy confere benefits in this setting.